Agilent and Gene Logic Team up for Joint Systems-Based Research and Discovery Projects
News Apr 24, 2007
Both companies contribute complementary skills and resources. Gene Logic offers an extensive biorepository of tissue samples with detailed clinical histories, reference databases, and expertise in generating high-quality genomics data for the pharmaceutical and biotechnology industries.
Agilent contributes its diverse, application-based microarray workflow solutions, including the GeneSpring bioinformatics system for complex data analysis. This relationship is also intended to take advantage of both companies’ channels into academic and commercial life science sectors.
"There is real synergy between our organizations for unlocking the mysteries of disease mechanisms," said Yvonne Linney, Agilent general manager, Genomics. "As such, our teams will tackle projects such as clinical profiling for toxicology and pathway mapping to assist researchers in both academia and pharma."
Gene Logic has achieved Agilent Certified Microarray Service Provider (CSP) status, which is awarded to labs passing a rigorous set of assessments. The Gene Logic lab demonstrated its proficiency in analyzing Agilent 60-mer oligo microarrays using the complete Agilent system; sample quality control using the Agilent 2100 Bioanalyzer; sample labeling using Agilent reagents and protocols; hybridization using SureHyb chambers; microarray analysis using the Agilent scanner and feature extraction software; and final data analysis using the GeneSpring bioinformatics platform. The company joins an elite group of nine other Agilent CSPs worldwide.
"We’re tremendously excited about applying Agilent’s cutting-edge technology platform to serve pharmaceutical developers’ increasing need to understand the molecular causes of disease and response to candidate therapies," said Larry Tiffany, general manager, Genomics for Gene Logic.
Tiffany continued, "We are convinced that combining our capabilities will accelerate the development of new preclinical and clinical assays and allow us to provide a more comprehensive set of solutions to our customers."
Using EBX reagents, researchers have converted the C-terminal carboxylic acid of peptides into a carbon-carbon triple bond - an alkyne (in chemical jargon a "decarboxylative alkynylation"). The alkyne moiety is a very valuable functional group that can be used to further modify the peptides.READ MORE